Annual Report

The report presents 2025 as a year of strategic refocusing after divestiture of the pharmaceutical distribution segment, with group revenue of RMB4.917 billion and industrial-segment growth. The company highlights its Suxiao Jiuxin public-welfare initiative, which reached over 600 million audience touchpoints, upgraded more than 6,000 pharmacies into emergency outposts, and trained 26,000 rescue personnel. It also reports a sustainability task force overseeing sustainability reporting and identifies energy, water, emissions, effluents and waste, occupational health and safety, and diversity as key topics. The report points readers to a separate 2025 Sustainability Report for further FY2025 detail.

Report type

Annual Report

Class

Financial

Scope

Full report

Fiscal year

2025

Period

Ends 31 December 2025

Language

English

Pages

 

File size